LEQEMBI IQLIK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LEQEMBI IQLIK (LEQEMBI IQLIK).
Monoclonal antibody targeting aggregated soluble and insoluble forms of amyloid beta, reducing amyloid plaques in the brain.
| Metabolism | Degraded into small peptides and amino acids via general protein catabolism; no CYP enzyme involvement. |
| Excretion | Primarily proteolytic catabolism to amino acids; renal elimination of intact drug is negligible (<1%). Biliary/fecal excretion is not a major route. |
| Half-life | Terminal half-life approximately 24.6 days (range 23-27 days) in patients with Alzheimer's disease; supports monthly intravenous dosing. |
| Protein binding | Approximately 90% bound to plasma proteins (primarily albumin and immunoglobulins). |
| Volume of Distribution | Approximately 0.07 L/kg (central volume); limited to plasma and interstitial fluid, consistent with large monoclonal antibody. |
| Bioavailability | Not applicable; administered intravenously with 100% bioavailability. Subcutaneous or intramuscular routes not approved. |
| Onset of Action | IV infusion: Clinical effects on amyloid beta plaque reduction observed within 3 months; cognitive benefit typically assessed at 6-12 months. |
| Duration of Action | Sustained amyloid reduction lasting up to 12-18 months after treatment cessation; clinical effects persist for months after last dose. |
Lecanemab (LEQEMBI IQLIK) for Alzheimer disease: 10 mg/kg IV infusion every 2 weeks, diluted in 250 mL saline, administered over approximately 1 hour. Initiate with 1 mg/kg IV on day 0 and 3 mg/kg IV on day 14 for titration, then 10 mg/kg IV every 2 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment recommended for mild to moderate renal impairment; insufficient data for severe renal impairment (eGFR <30 mL/min/1.73 m²) — use with caution. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A); not studied in moderate or severe hepatic impairment (Child-Pugh B or C) — use only if benefit outweighs risk. |
| Pediatric use | Safety and efficacy not established in pediatric patients (<18 years); no dose recommendations available. |
| Geriatric use | No specific dose adjustment required for elderly patients based on age alone; consider renal function (eGFR) and overall health status; monitor for infusion-related reactions and amyloid-related imaging abnormalities (ARIA). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LEQEMBI IQLIK (LEQEMBI IQLIK).
| Breastfeeding | Unknown if lecanemab is excreted in human milk; endogenous IgG is present in breast milk. M/P ratio not determined. Weigh benefits against potential infant exposure. |
| Teratogenic Risk | No human data available; animal studies show developmental toxicity including reduced fetal weight and skeletal variations at doses below clinical exposure. In first trimester, risk cannot be excluded. Second and third trimester: potential for fetal harm unknown. Monoclonal antibodies cross placenta increasingly after 20 weeks gestation. |
■ FDA Black Box Warning
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemorrhage/hemosiderin deposition), which can be fatal.
| Serious Effects |
None known.
| Precautions | Amyloid-related imaging abnormalities (ARIA), infusion-related reactions, hypersensitivity reactions, and risk of symptomatic ARIA requiring monitoring via MRI. |
Loading safety data…
| Fetal Monitoring |
| Monitor for infusion reactions (hypotension, hypoxia); perform baseline and periodic liver function tests. Assess for amyloid-related imaging abnormalities (ARIA) with MRI if neurological symptoms emerge. Fetal monitoring: consider serial ultrasound for growth and amniotic fluid volume if used during second/third trimester. |
| Fertility Effects | No human fertility data. In animal studies, no adverse effects on male or female fertility at doses up to 300 mg/kg every 2 weeks (AUC exposure 11 times the clinical exposure). |